Phytocannabinoids and Synthetic Cannabinoids: What Patients Should Know
Cannabinoid medicines are attracting attention in Australia for cancer-related symptoms, persistent pain, nausea, sleep problems and treatment-associated discomfort. The word “cannabinoid” covers several different substances, however, and products that sound similar can have very different sources, strengths, legal status and safety profiles.
Phytocannabinoids are compounds produced by the cannabis plant, including tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG) and others. Synthetic cannabinoids may refer to regulated medicines manufactured to reproduce or modify cannabinoid activity, or unregulated laboratory-made drugs sold as “Spice” or “Kronic”. Patients need to separate these categories before considering any treatment.
| Feature | Plant-derived cannabinoids | Regulated synthetic cannabinoids | Unregulated synthetic cannabinoids |
|---|---|---|---|
| Source | Extracted or purified from cannabis plants | Manufactured in a laboratory | Informal or illicit laboratory production |
| Examples | THC, CBD, CBG, whole-plant extracts | Dronabinol, nabilone and related medicines | Products sold as Spice, Kronic or herbal incense |
| Quality control | Depends on authorised manufacturing and testing | Standardised dose and pharmaceutical controls | Frequently unknown or unreliable |
| Typical concerns | Sedation, dizziness, drug interactions and THC effects | Similar cannabinoid effects, with product-specific risks | Severe toxicity, agitation, seizures and cardiovascular effects |
| Australian access | Prescription medicinal cannabis under applicable rules | Prescription-only where approved or accessed through schemes | Illegal and unsafe |
Understanding The Main Cannabinoid Categories
Phytocannabinoids are naturally occurring cannabis compounds. THC is primarily associated with intoxication, altered perception and appetite effects, while CBD does not usually produce the same “high”. Their effects can change when they are combined with terpenes, minor cannabinoids, oils, food and other medicines. A full-spectrum preparation may contain several plant compounds, whereas an isolate is designed to provide one principal cannabinoid.
A synthetic cannabinoid is not automatically dangerous simply because it is made in a laboratory. Some pharmaceutical products use manufactured molecules so that clinicians can provide a consistent dose. Dronabinol, for example, is a laboratory-produced form of THC, and nabilone is a related medicine used in specific clinical circumstances. These regulated medicines are very different from illicit products made to activate cannabinoid receptors unpredictably.
The phrase “synthetic cannabis” causes particular confusion. In Australia, it has often described illicit receptor-activating chemicals rather than genuine cannabis. These substances may be sprayed onto plant material or sold in liquids. Their chemical structure can change quickly, so a previous experience with one packet does not predict the effects of another.
How Effects And Risks Differ
Plant-derived THC can cause drowsiness, impaired coordination, anxiety, rapid heartbeat, dry mouth and problems with short-term attention. CBD is often perceived as gentler, yet it can still cause sleepiness, diarrhoea, appetite changes or interactions with medicines processed by the liver. The amount of THC, the ratio of THC to CBD, the route of administration and the patient’s tolerance all matter.
Pharmaceutical synthetic cannabinoids may provide a more predictable amount of an active ingredient, which can help with prescribing and monitoring. They can still produce dizziness, sedation, mood changes, nausea or changes in blood pressure. A standardised medicine is easier to study than an unknown extract, but “standardised” does not mean suitable for every person or condition.
Unregulated synthetic cannabinoids present a different level of concern. They may bind strongly to cannabinoid receptors and have a longer or harsher effect than plant THC. Reported harms include panic, hallucinations, vomiting, chest pain, kidney injury, seizures, unconsciousness and dangerous agitation. Emergency symptoms after any unknown cannabinoid product warrant an immediate call to 000 in Australia.
Evidence For Cancer-Related Symptoms And Pain
Cannabinoid medicines are not interchangeable with anticancer treatment. Current clinical use generally focuses on symptoms such as chemotherapy-induced nausea and vomiting when standard medicines have not worked adequately, selected pain syndromes, appetite concerns or sleep disturbance. Evidence for cancer pain is mixed, and benefits can vary widely between individuals. A product should never replace surgery, chemotherapy, radiotherapy, immunotherapy or a specialist’s advice without a properly supervised decision.
Pain itself also needs careful assessment. Nerve pain, inflammatory pain, bone pain, muscle spasm and pain related to oral disease may respond differently to medicines. CBD or THC may help some people, while others experience little benefit or unacceptable sedation. Patients considering oral pain relief options should also seek dental, oncology or palliative-care assessment when symptoms involve ulcers, infection, swelling, bleeding or difficulty swallowing.
A responsible clinician will establish a baseline, set a measurable goal and review the result. Useful goals might include sleeping for longer, reducing breakthrough pain or improving the ability to eat. Keeping a record of dose, timing, pain intensity, alertness and side effects can make follow-up more meaningful than relying on memory.
Product Quality And Administration In Australia
In Australia, medicinal cannabis is generally prescription-only. Access may involve a medical practitioner using the Special Access Scheme or Authorised Prescriber pathway, depending on the circumstances. The Therapeutic Goods Administration regulates the framework, while state and territory rules can affect prescribing, supply and other practical matters. Most medicinal cannabis products are not broadly subsidised through the Pharmaceutical Benefits Scheme, so cost can be significant.
The Australian market includes oils, capsules, oral liquids, flower and some inhaled products, with availability changing over time. A patient in Sydney or Melbourne may find several authorised pharmacies and telehealth services, while someone in regional Queensland, Western Australia or Tasmania may face longer delivery times and fewer local options. A prescription does not remove the need to check the dispensing pharmacy, product instructions and follow-up arrangements.
Route of administration changes how quickly effects begin and how long they last. Oral oils and capsules may take one to several hours to have their full effect and can last for many hours. Inhaled products act sooner but introduce respiratory and dosing concerns. Rectal products require particular attention to formulation, hygiene, absorption and clinical supervision; internet instructions are not a substitute for advice from a qualified practitioner.
Some online providers describe individualised plans, consultation pathways and ongoing support. Patients can review the provider’s approach, but should still verify the prescriber’s Australian registration, the product’s legal supply route, laboratory testing and the identity of the dispensing pharmacy. Be cautious of claims promising to cure cancer, eliminate all pain or provide a universally effective formulation.
Interactions, Daily Life And Legal Responsibilities
Cannabinoids can interact with anticoagulants, sedatives, anticonvulsants, antidepressants, opioids and other medicines. CBD and THC may affect liver enzymes involved in drug metabolism. People with a history of psychosis, unstable heart disease, severe liver impairment, pregnancy or breastfeeding need specific medical advice before considering cannabinoid treatment. Older adults may be more vulnerable to falls, confusion and excessive sedation.
Driving is a major Australian consideration. THC can remain detectable after noticeable impairment has faded, and roadside drug-testing rules apply in several jurisdictions. In New South Wales, Victoria and other states, a person may face legal consequences for driving with THC detected, even if the medicine was prescribed. Patients should ask their doctor about driving, workplace testing, operating machinery and travel restrictions rather than assuming a prescription provides protection.
Everyday routines also influence risk. Taking an oil before a long commute across Brisbane or Melbourne may be unsuitable if sedation develops later. Alcohol, sleep deprivation and cannabis products can compound impairment, while fatty meals may change absorption of some oral formulations. Store medicines securely, keep them in original packaging and never share them with family members, including teenagers.
For people exploring supportive lifestyle measures, dietary plans should be discussed with an oncology dietitian rather than adopted from social media. A ketogenic dietary plan may be inappropriate for people with weight loss, malnutrition, diabetes, kidney disease or treatment-related gastrointestinal problems. Diet and cannabinoid decisions should fit the broader cancer-care plan.
Choosing A Safer Path With Your Care Team
Before starting, write down the exact product name, cannabinoid content, batch information, route, intended purpose and proposed starting dose. Ask whether the product is plant-derived, a purified isolate, a pharmaceutical synthetic cannabinoid or an unregulated substance. “Natural”, “organic” and “medical grade” are not enough evidence of quality unless the supply chain and testing can be verified.
A cautious prescribing approach usually starts low and changes one factor at a time. The clinician may gradually increase the dose, alter the THC-to-CBD balance or stop treatment if there is no meaningful improvement. Patients should report severe anxiety, fainting, persistent vomiting, confusion, hallucinations, allergic symptoms or worsening pain promptly. Sudden cessation may also need guidance when a product has been used regularly.
Family members and carers can help by recording doses and observing changes in alertness, balance, mood and eating. This is especially useful in palliative care, where comfort and function matter as much as a numerical pain score. A multidisciplinary team may include a GP, oncologist, pharmacist, pain specialist, palliative-care clinician and, when appropriate, a psychologist or dietitian.
The safest comparison is therefore not “natural versus chemical”. It is a comparison of a clearly identified medicine, reliable manufacturing, appropriate evidence, legal supply, careful dosing and suitable clinical monitoring. A plant-derived extract can carry meaningful risks, while a regulated synthetic medicine may be more predictable than an unknown cannabis-labelled product.
If you are considering cannabinoid treatment for cancer symptoms or pain, take your current medicines, medical history and treatment goals to an Australian-registered doctor or pharmacist. Ask for a documented plan covering product identity, dosing, interactions, driving, follow-up and what to do if side effects occur. Do not use illicit synthetic cannabinoids or delay urgent cancer care while seeking an alternative option.